j. immunotherapy cancer
The Journal for ImmunoTherapy of Cancer (JITC) is a leading, peer-reviewed, open-access publication dedicated to advancing the rapidly evolving field of tumor immunology and cancer immunotherapy. Published by BMJ in partnership with the Society for Immunotherapy of Cancer (SITC), the journal serves as a premier platform for disseminating high-impact research that bridges fundamental immunology and clinical oncology. Its scope encompasses the full spectrum of immunotherapy, including immune checkpoint blockade, adoptive cell therapies, cancer vaccines, oncolytic viruses, and combination strategies, as well as mechanisms of immune resistance and tumor microenvironment interactions. JITC publishes original research articles, comprehensive reviews, brief reports, and clinical trial results, alongside commentaries and consensus guidelines that reflect the collaborative expertise of the global immunotherapy community. The target audience includes basic and translational scientists, clinical oncologists, immunologists, and pharmaceutical researchers seeking cutting-edge developments in cancer immunology. A hallmark of the journal is its rigorous peer-review process and rapid publication model, ensuring timely dissemination of critical findings. With a 2026 Impact Factor of 12.4690 and a top-tier JCR Quartile ranking of Q1, JITC is consistently recognized among the most influential journals in oncology and immunology. Its open-access policy maximizes global visibility and accessibility, fostering knowledge exchange and accelerating the translation of laboratory discoveries into effective clinical therapies for patients with cancer.